ArticleCancers2026
Targeting Steroid-Metabolizing Enzymes with 15β-Substituted Estrone Analogues: Dual Discovery of AKR1C2/17β-HSD1 Inhibitors and a Fluorescent 17β-HSD1 Ligand.
Vivien Resch, Marija Gjorgoska, Eva Hafner, Ildikó Bacsa, Benjamin Kovács, Tomaž Büdefeld, Attila Hunyadi, Ildikó Huliák, Mónika Kiricsi, Gábor Paragi and 2 more
Abstract read
In one paragraphArticle in Cancers, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
12 authors.
Vivien ReschDepartment of Medicinal Chemistry, University of Szeged, Dóm tér 8, H-6720 Szeged, Hungary.
Marija GjorgoskaInstitute of Biochemistry and Molecular Genetics, Faculty of Medicine, University of Ljubljana, Vrazov trg 2, 1000 Ljubljana, Slovenia.
Eva HafnerInstitute of Biochemistry and Molecular Genetics, Faculty of Medicine, University of Ljubljana, Vrazov trg 2, 1000 Ljubljana, Slovenia.
Ildikó BacsaInstitute of Pharmacognosy, University of Szeged, Eötvös u. 6, H-6720 Szeged, Hungary.
Benjamin KovácsInstitute of Pharmacognosy, University of Szeged, Eötvös u. 6, H-6720 Szeged, Hungary.ORCID 0009-0004-0799-1908 Tomaž BüdefeldInstitute of Biochemistry and Molecular Genetics, Faculty of Medicine, University of Ljubljana, Vrazov trg 2, 1000 Ljubljana, Slovenia.
Attila HunyadiInstitute of Pharmacognosy, University of Szeged, Eötvös u. 6, H-6720 Szeged, Hungary.ORCID 0000-0003-0074-3472 Ildikó HuliákDepartment of Biochemistry and Molecular Biology, University of Szeged, Közép fasor 52, H-6726 Szeged, Hungary.
Mónika KiricsiDepartment of Biochemistry and Molecular Biology, University of Szeged, Közép fasor 52, H-6726 Szeged, Hungary.ORCID 0000-0002-8416-2052 Gábor ParagiDepartment of Medicinal Chemistry, University of Szeged, Dóm tér 8, H-6720 Szeged, Hungary.ORCID 0000-0001-5408-1748 Tea Lanišnik RižnerInstitute of Biochemistry and Molecular Genetics, Faculty of Medicine, University of Ljubljana, Vrazov trg 2, 1000 Ljubljana, Slovenia.ORCID 0000-0002-3453-4081 Erzsébet MernyákInstitute of Pharmacognosy, University of Szeged, Eötvös u. 6, H-6720 Szeged, Hungary.ORCID 0000-0003-4494-1817 Funding
National Research, Development and Innovation Office SNN 139323The Slovenian Research and Innovation Agency N1-0234 and P3-0449
6 · The paper itselfAbstract
BACKGROUND/
objectivesAldo-keto reductase isoforms AKR1C1-3 and 17β-hydroxysteroid dehydrogenase 1 and 2 (17β-HSD1 and 17β-HSD2) are key enzymes in steroid metabolism and validated targets in hormone-dependent cancers.
methodsIn this study, Δ
resultsThe Δ
conclusionsThese findings identify Δ
Indexed as
17β-HSD1 enzymeAKR1C1–3 enzymesantiproliferativechemoresistancefluorescent labelinginhibitor
Identifiers
PMID42352425
PMCPMC13296439
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390